NHSA Releases 2026 NRDL Update Adding 107 Drugs Including Million‑Yuan CAR‑T Therapies – Ninth List Adjustment Since the Agency’s Establishment
China's National Healthcare Security Administration (NHSA) released the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work‑Related Injury Insurance (NRDL) and the Commercial Health Insurance Innovative Drug List…
IMPACT Therapeutics Wins Final EC Marketing Authorization for Senaparib (Sepalna) – Highly Potent PARP1/2 Inhibitor Approved in the EU for Ovarian Cancer Maintenance
IMPACT Therapeutics (HKG: 7630) announced that the European Commission (EC) has granted final marketing authorization for senaparib (overseas brand name: Sepalna), the company's internally developed innovative drug, for the maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal…
Where biopharma's biggest deals take shape!
Betta Pharmaceuticals Licenses Next‑Generation ALK Inhibitor Ensartinib to Mankind Pharma for India – Upfront, Milestones and Tiered Royalties in Exclusive Territory Deal
Betta Pharmaceuticals (SHE: 300558) announced that it has entered into a licensing agreement with leading Indian pharmaceutical company Mankind Pharma (BOM: 543904; NSE: MANKIND), granting Mankind exclusive rights to ensartinib…
NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…
